nach oben

PharmacoEconomics

Erschienen in:

01.08.2016 | Systematic Review

Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension

verfasst von: Shuyan Gu, Huimei Hu, Hengjin Dong

Erschienen in: PharmacoEconomics | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The increasing survival of patients with pulmonary arterial hypertension (PAH) has shifted attention towards the disease burden that PAH imposes on patients and healthcare systems. Most studies emphasize epidemiology and medications, while large observational studies reporting on the health-related quality of life (HRQOL) of patients with PAH are lacking.

Objective

Our objective was to study the HRQOL of patients with PAH and to summarize the factors that influence it.

Methods

We conducted systematic literature searches in English (PubMed, Web of Knowledge, ScienceDirect and OVID) and Chinese (China National Knowledge Infrastructure, Wanfang Data, Chongqing VIP and SinoMed) databases to identify studies published from 2000 to 2015 assessing the HRQOL of patients with PAH. Search results were independently reviewed and extracted by two reviewers.

Results

Of 3392 records identified in the initial search, 20 eligible papers (19 English, 1 Chinese) were finally included. Studies used a range of instruments; the generic 36-item Short Form Survey (SF-36) was the most widely used, and the disease-specific Cambridge Pulmonary Hypertension Outcome Survey (CAMPHOR) was the second mostly widely used. Mean HRQOL scores assessed via the SF-36 (physical component summary [PCS] 25.4–80.1; mental component summary [MCS] 33.2–76.0) and CAMPHOR (symptom scores 3.1–17; total HRQOL 2.8–12.6; activity scores 3.8–18.1) varied across studies, reporting decreased HRQOL in patients. Mental health (depression, anxiety, stress), physical health (exercise capacity, symptoms) and medical therapies were reported to affect HRQOL.

Conclusion

We found that PAH places a substantial burden on patients, particularly in terms of HRQOL; however, the paucity of large observational studies in this area requires the attention of researchers, especially in China.

Nur mit Berechtigung zugänglich

Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–36.CrossRefPubMed

Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111–7.CrossRefPubMed

Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655–65.CrossRefPubMed

Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917–28.CrossRefPubMed

Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–54.CrossRefPubMed

McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–619.CrossRefPubMed

Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S–12S.CrossRefPubMed

American Lung Association. Pulmonary arterial hypertension [online]. http://www.lung.org/lung-disease/pulmonary-arterial-hypertension/. Accessed 22 July 2015.

Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007;132:373–9.CrossRefPubMed

10.

Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137:376–87.CrossRefPubMed

11.

McDonough A, Matura LA, Carroll DL. Symptom experience of pulmonary arterial hypertension patients. Clin Nurs Res. 2011;20:120–34.CrossRefPubMed

12.

Flattery MP, Pinson JM, Savage L, Salyer J. Living with pulmonary artery hypertension: patients’ experiences. Heart Lung. 2005;34:99–107.CrossRefPubMed

13.

Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev. 2015;24:621–9.CrossRefPubMed

14.

Buys R, Avila A, Cornelissen VA. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med. 2015;15:40.CrossRefPubMedPubMedCentral

15.

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–30.CrossRefPubMed

16.

Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30:104–9.CrossRefPubMed

17.

Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J. 2007;30:1103–10.CrossRefPubMed

18.

Mikhail GW, Prasad SK, Li W, Rogers P, Chester AH, Bayne S, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J. 2004;25:431–6.CrossRefPubMed

19.

Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–57.CrossRefPubMed

20.

Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47:2049–56.CrossRefPubMed

21.

Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142:448–56.CrossRefPubMed

22.

McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244–9.CrossRefPubMed

23.

Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529–35.CrossRefPubMed

24.

Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:394–403.CrossRefPubMedPubMedCentral

25.

Cha KS, Cho KI, Seo JS, Choi JH, Park YH, Yang DH, et al. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study). Am J Cardiol. 2013;112:1834–9.CrossRefPubMed

26.

Duffels M, Vis JC, van Loon R, Nieuwkerk PT, van Dijk A, Hoendermis ES, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down’s syndrome. Am J Cardiol. 2009;103:1309–15.CrossRefPubMed

27.

Vis JC, Duffels MG, Mulder P, de Bruin-Bon RH, Bouma BJ, Berger RM, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;164:64–9.CrossRefPubMed

28.

Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1–320.CrossRefPubMed

29.

Mazzanti G, Albini A, Palazzini M, Monti E, Bachetti C, Rinaldi A, et al. A randomized open label study comparing first-line treatment with bosentan or sildenafil in Pulmonary Arterial Hypertension (PAH). Eur Heart J. 2013;341:186–7.

30.

Crackett RM, Hall A, Day MB, Desoyza JR, Small T, Fisher AJ, et al. Treatment outcomes in pulmonary arterial hypertension (PHA) associated with systemic sclerosis (Sscl.) in matched groups using either bosentan or sildenafil monotherapy. J Heart Lung Transpl. 2013;32S:S301.CrossRef

31.

Matura LA, Carroll DL. Human responses to pulmonary arterial hypertension: review of the literature. J Cardiovasc Nurs. 2010;25:420–7.CrossRefPubMed

32.

Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thoracic Soc. 2008;5:623–30.CrossRef

33.

Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S. Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review. Chest. 2014;146:686–708.CrossRefPubMed

34.

Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8:2–10.CrossRefPubMed

35.

Zeng X, Liu H, Chen X, Leng W. Meta-analysis series 4: the methodological quality assessment tools for observational study. Chinese J Evid Based Cardiovasc Med. 2012;04:297–9.

36.

Cao S. The application of meta-analysis of observational studies in social factors and health—illustrated by the case of smoking. Hubei: Huazhong University Of Science And Technology; 2014.

37.

Rostom A, Dubé C, Cranney A, Saloojee N, Sy R, Mack D, et al. Celiac disease. Rockville (MD): US Agency for Healthcare Research and Quality; 2004 Sep. (Evidence Reports/Technology Assessments, No. 104.) Appendix D. Quality Assessment Forms [online]. http://www.ncbi.nlm.nih.gov/books/NBK35156/. Accessed 14 Dec 2015.

38.

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [online]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 14 Dec 2015.

39.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.CrossRefPubMed

40.

Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest. 2004;126:1452–9.CrossRefPubMed

41.

Taichman DB, Shin J, Hud L, Archer-Chicko C, Kaplan S, Sager JS, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res. 2005;6.

42.

White J, Hopkins RO, Glissmeyer EW, Kitterman N, Elliott CG. Cognitive, emotional, and quality of life outcomes in patients with pulmonary arterial hypertension. Respir Res. 2006;7:55.CrossRefPubMedPubMedCentral

43.

Zlupko M, Harhay MO, Gallop R, Shin J, Archer-Chicko C, Patel R, et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med. 2008;102:1431–8.CrossRefPubMed

44.

Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD. Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J. 2011;38:608–16.CrossRefPubMedPubMedCentral

45.

Matura LA, McDonough A, Carroll DL. Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. Eur J Cardiovasc Nurs. 2012;11:51–61.CrossRefPubMed

46.

Matura LA, McDonough A, Carroll DL. Predictors of health-related quality of life in patients with idiopathic pulmonary arterial hypertension. J Hosp Palliat Nurs. 2012;14:283–92.CrossRef

47.

Swetz KM, Shanafelt TD, Drozdowicz LB, Sloan JA, Novotny PJ, Durst LA, et al. Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey. J Heart Lung Transpl. 2012;31:1102–8.CrossRef

48.

Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs. 2014;29:178–84.CrossRefPubMed

49.

Matura LA, McDonough A, Hanlon AL, Carroll DL, Riegel B. Sleep disturbance, symptoms, psychological distress, and health-related quality of life in pulmonary arterial hypertension. Eur J Cardiovasc Nurs. 2015;14:423–30.CrossRefPubMed

50.

Talwar A, Sahni S, Kim EJ, Verma S, Kohn N. Dyspnea, depression and health related quality of life in pulmonary arterial hypertension patients. J Exerc Rehabil. 2015;11:259–65.CrossRefPubMedPubMedCentral

51.

Matura LA, McDonough A, Carroll DL. Symptom interference severity and health-related quality of life in pulmonary arterial hypertension. J Pain Symptom Manage. 2016;51:25–32.CrossRefPubMed

52.

Wilkens H, Grimminger F, Hoeper M, Stahler G, Ehlken B, Plesnila-Frank C, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med. 2010;104:902–10.CrossRefPubMed

53.

Roman A, Barbera JA, Castillo MJ, Munoz R, Escribano P. Health-related quality of life in a national cohort of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Arch Bronconeumol. 2013;49:181–8.CrossRefPubMed

54.

McCabe C, Bennett M, Doughty N, Ross RM, Sharples L, Pepke-Zaba J. Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest. 2013;144:522–30.CrossRefPubMedPubMedCentral

55.

Vanhoof JMM, Delcroix M, Vandevelde E, Denhaerynck K, Wuyts W, Belge C, et al. Emotional symptoms and quality of life in patients with pulmonary arterial hypertension. J Heart Lung Transpl. 2014;33:800–8.CrossRef

56.

Cui M, Lin M, Zhang Q. The correlation between health behavior and quality of life in patients with pulmonary arterial hypertension. Chin J Prevent Control Chronic Dis. 2014;22:202–4.

57.

Small M, Piercy J, Pike J, Cerulli A. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy. Adv Ther. 2014;31:168–79.CrossRefPubMed

58.

Yorke J, Armstrong I. The assessment of breathlessness in pulmonary arterial hypertension: reliability and validity of the Dyspnoea-12. Eur J Cardiovasc Nurs. 2014;13:506–14.CrossRefPubMed

59.

Blok IM, van Riel A, Schuuring MJ, Duffels MG, Vis JC, van Dijk A, et al. Decrease in quality of life predicts mortality in adult patients with pulmonary arterial hypertension due to congenital heart disease. Neth Heart J. 2015;23:278–84.CrossRefPubMedPubMedCentral

60.

Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;125:1928–52.CrossRefPubMedPubMedCentral

61.

Tartavoulle T. A predictive model of the effects of depression, anxiety, stress, six minute walk distance, and social support on health related quality of life in an adult pulmonary hypertension population. Clin Nurse Spec. 2014;28:E40.CrossRef

62.

Batal O, Khatib OF, Bair N, Aboussouan LS, Minai OA. Sleep quality, depression, and quality of life in patients with pulmonary hypertension. Lung. 2011;189:141–9.CrossRefPubMed

63.

Ulrich S, Fischler M, Speich R, Bloch KE. Sleep-related breathing disorders in patients with pulmonary hypertension. Chest. 2008;133:1375–80.CrossRefPubMed

64.

McCollister DH, Beutz M, McLaughlin V, Rumsfeld J, Masoudi FA, Tripputi M, et al. Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics. 2010;51:339.CrossRefPubMed

65.

Lowe B, Grafe K, Ufer C, Kroenke K, Grunig E, Herzog W, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med. 2004;66:831–6.CrossRefPubMed

66.

European Pulmonary Hypertension Association. The impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers: results from an international survey [online]. http://www.phaeurope.org/wp-content/uploads/PAH_Survey_FINAL.pdf. Accessed 3 Jan 2016.

67.

Harzheim D, Klose H, Pinado FP, Ehlken N, Nagel C, Fischer C, et al. Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Res. 2013;14:104.CrossRefPubMedPubMedCentral

68.

Kim EJ, Verma S, Sahni S, Athaanasiou K, Patel P, Kohn N, et al. Dyspnea, depression, and health related quality of life [HRQOL] in patients with pulmonary artery hypertension [PAH]. Chest. 2013;144S.

69.

Halank M, Einsle F, Lehman S, Bremer H, Ewert R, Wilkens H, et al. Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung. 2013;191:337–43.CrossRefPubMed

70.

Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin. 2009;25:2479–85.CrossRefPubMed

71.

Cicero C, Franchi SM, Barreto AC, Lopes AA. Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension. Arq Bras Cardiol. 2012;99:876–85.CrossRefPubMed

72.

Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transpl. 2007;26:181–7.CrossRef

73.

Wang RC, Jiang FM, Zheng QL, Li CT, Peng XY, He CY, et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Respir Med. 2014;108:531–7.CrossRefPubMed

74.

Udeoji DU, Schwarz ER. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis. 2013;7:39–49.CrossRefPubMed

75.

Croxtall JD, Lyseng-Williamson KA. Tadalafil: in pulmonary arterial hypertension. Drugs. 2010;70:479–88.CrossRefPubMed

76.

Somaini SU, Vatandaslar S, Huber LC, Treder U, Breitenstein A, Speich R. Imatinib improves hemodynamics and quality of life in pulmonary arterial hypertension. Am J Resp Crit Care. 2011;183.

77.

Jacobs W, Vonk-Noordegraaf A. Epoprostenol in pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2009;5:83–90.CrossRefPubMed

78.

Ewert R, Glaser S, Bollmann T, Schaper C. Inhaled iloprost for therapy in pulmonary arterial hypertension. Expert Rev Respir Med. 2011;5:145–52.CrossRefPubMed

79.

Schuuring MJ, Vis JC, van Dijk AP, van Melle JP, Vliegen HW, Pieper PG, et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013;15:690–8.CrossRefPubMed

80.

McLaughlin VV. Medical management of primary pulmonary hypertension. Expert Opin Pharmacother. 2002;3:159–65.CrossRefPubMed

81.

Chen H, Rosenzweig EB, Gotzkowsky SK, Arneson C, Nelsen AC, Bourge RC. Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension. Health Qual Life Outcomes. 2013;11:31.CrossRefPubMedPubMedCentral

82.

Rubenfire M, Lippo G, Bodini BD, Blasi F, Allegra L, Bossone E. Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need. Chest. 2009;136:597–603.CrossRefPubMed

83.

Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R, et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J. 2006;28:808–15.CrossRefPubMed

84.

Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transpl. 2008;27:124–30.CrossRef

85.

Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, et al. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J. 2008;15:77–83.CrossRefPubMedPubMedCentral

86.

Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, et al. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011;16:1235–40.CrossRefPubMed

87.

Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014;43:1106–13.CrossRefPubMed

88.

Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res. 2013;22:1161–75.CrossRefPubMed

89.

Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Appl Health Econ Health Policy. 2011;9:293–303.CrossRefPubMed

90.

Krumholz HM. Patient-centered medicine: the next phase in health care. Circ Cardiovasc Qual Outcomes. 2011;4:374–5.CrossRefPubMed

91.

Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44:681–92.CrossRefPubMed

92.

Goodlin SJ, Hauptman PJ, Arnold R, Grady K, Hershberger RE, Kutner J, et al. Consensus statement: palliative and supportive care in advanced heart failure. J Card Fail. 2004;10:200–9.CrossRefPubMed

93.

Jaarsma T, Beattie JM, Ryder M, Rutten FH, McDonagh T, Mohacsi P, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:433–43.CrossRefPubMed

94.

Pantilat SZ, Steimle AE. Palliative care for patients with heart failure. JAMA. 2004;291:2476–82.CrossRefPubMed

95.

Rizzieri AG, Verheijde JL, Rady MY, McGregor JL. Ethical challenges with the left ventricular assist device as a destination therapy. Philos Ethics Humanit Med. 2008;3:20.CrossRefPubMedPubMedCentral

96.

Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75.CrossRefPubMed

97.

Arena R, Cahalin LP, Borghi-Silva A, Myers J. The effect of exercise training on the pulmonary arterial system in patients with pulmonary hypertension. Prog Cardiovasc Dis. 2015;57:480–8.CrossRefPubMed

Titel: Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension
verfasst von: Shuyan Gu
Huimei Hu
Hengjin Dong
Publikationsdatum: 01.08.2016
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 8/2016
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-016-0395-y

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria

Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective

Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges

Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial

A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions

The Impact of Different DCE-Based Approaches When Anchoring Utility Scores